Peptide education
Dalbavancin, oritavancin, and telavancin
Dalbavancin, oritavancin, and telavancin are three distinct intravenous antibiotics in the lipoglycopeptide group. Their U.S. labels cover specific infections caused by susceptible Gram-positive bacteria.
Dalvance and the oritavancin products have labeled uses for specified acute skin infections. Vibativ covers specified complicated skin infections and selected hospital-acquired or ventilator-associated S. aureus pneumonia.
Overview
Quick answer
The medicines are not interchangeable as a group. Their labeled populations, infection sites, preparation instructions, and safety warnings differ.
Which product is also labeled for certain pneumonia?
Vibativ is labeled for adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible S. aureus when alternative treatments are unsuitable.
Are these medicines labeled for children?
Dalvance is labeled for acute skin infections in pediatric patients, including from birth. The cited Orbactiv, Kimyrsa, and Vibativ labels specify adult uses; pediatric safety and effectiveness are not established.
What does oritavancin do to clotting tests?
Orbactiv and Kimyrsa can falsely prolong the aPTT test for up to 120 hours. Intravenous unfractionated heparin is contraindicated for 120 hours after either product.
What makes Vibativ different for safety?
Its boxed warnings include kidney toxicity, potential fetal harm, and increased mortality versus vancomycin in a pneumonia subgroup with pre-existing moderate or severe kidney impairment.
Evidence
Evidence snapshot
The studies compared dalbavancin with a vancomycin regimen that could be followed by oral linezolid.
Pooled early response at 48 to 72 hours, not final cure, with dalbavancin versus the comparator strategy.
Oritavancin can falsely prolong aPTT; the intravenous unfractionated heparin contraindication lasts 120 hours after administration.
The label highlights nephrotoxicity, embryo-fetal toxicity, and increased mortality in a renal-impaired pneumonia subgroup.
Claims
Common claims vs evidence
| Claim | Human evidence | Verdict |
|---|---|---|
| The three antibiotics have the same approved uses. | Their skin-infection labels differ in age and wording. Vibativ also has a restricted pneumonia indication for susceptible S. aureus. | Confirm the individual product and infection site. |
| A dalbavancin trial proves that all three antibiotics work equally well. | The DISCOVER studies tested dalbavancin against a vancomycin strategy, not against oritavancin or telavancin. | The result belongs to the studied medicine and comparator. |
| Orbactiv and Kimyrsa have identical preparation instructions. | The two oritavancin products have different vial strengths, infusion durations, preparation instructions, and compatible diluents. | Follow the label for the exact product. |
Bottom line
Main takeaway
These are three different prescription antibiotics, not three names for one drug.
Share kidney history, possible pregnancy, anticoagulants, and glycopeptide allergies before treatment.
The dalbavancin noninferiority result used an early skin-infection response and a specific comparator strategy.
Identity
What it is
These lipoglycopeptide antibacterials are administered intravenously. Their labels name susceptible Gram-positive organisms, including methicillin-resistant S. aureus for specified infections.
Infection site and bacterial susceptibility matter. The labels do not establish that every Gram-positive infection is an appropriate use.
Use context
Routes, doses, and cycle patterns
These label descriptions identify the medicine and intended population. Vial strength is not a patient dose; treatment and preparation depend on the exact product and clinical circumstances.
Human studies and product labels
Dalbavancin, Dalvance
- Purpose
- Acute bacterial skin and skin structure infections caused by designated susceptible bacteria
- Context
- U.S. prescription label for adults and pediatric patients
- Route
- Intravenous
Dalvance is supplied as a 500 mg single-dose vial. The label describes single-dose or two-dose options for adults and age- and weight-based pediatric treatment; kidney function affects the adult regimen.
Oritavancin, Orbactiv
- Purpose
- Acute bacterial skin and skin structure infections caused by designated susceptible bacteria
- Context
- U.S. prescription label for adults
- Route
- Intravenous
Orbactiv is supplied in 400 mg single-dose vials and its labeled adult course uses one infusion. Its preparation differs from Kimyrsa.
Oritavancin, Kimyrsa
- Purpose
- Acute bacterial skin and skin structure infections caused by designated susceptible bacteria
- Context
- U.S. prescription label for adults
- Route
- Intravenous
Kimyrsa is supplied in a 1,200 mg single-dose vial. It has different preparation instructions and infusion duration from Orbactiv.
Telavancin, Vibativ
- Purpose
- Complicated skin infection or selected hospital-acquired or ventilator-associated S. aureus pneumonia
- Context
- U.S. prescription label for adults
- Route
- Intravenous
Vibativ is supplied in a 750 mg single-dose vial. For the pneumonia indication, the label reserves use for situations where alternatives are unsuitable. Kidney function affects treatment decisions.
What varies
- Bacterial susceptibility: the named labels cover specified organisms and infection sites, not all infections.
- Kidney function: Dalvance and Vibativ have different renal considerations; the oritavancin labels have limited severe-impairment data.
- Anticoagulation: oritavancin and telavancin both affect coagulation testing, but their label contraindications are not identical.
Research
Research evidence
Controlled studies support individual products for defined infections. The dalbavancin trials below do not test the other two antibiotics.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| DISCOVER skin-infection studies | 1,312 randomized adults with acute bacterial skin and skin structure infections | Two randomized noninferiority trials | IV dalbavancin versus IV vancomycin with an option to switch to oral linezolid | In the pooled analysis, 525 of 659 adults randomized to dalbavancin and 521 of 653 randomized to the comparator met the early-response endpoint. At 48 to 72 hours, it required no increase in lesion area from baseline and a temperature consistently at or below 37.6 degrees Celsius on repeated measurement. Both trials met their noninferiority criterion. | The early endpoint and comparator strategy limit what can be inferred about other infections or antibiotics. | Strong |
| Orbactiv skin-infection studies | 1,987 adults with acute bacterial skin and skin structure infections | Two randomized, double-blind noninferiority trials described in the label | Orbactiv versus intravenous vancomycin | Early clinical response was assessed at 48 to 72 hours, with results reported separately for each trial. | Results concern the studied adult skin infections and do not establish efficacy for other sites. | Strong |
Cautions
Safety and unknowns
- Dalvance can cause serious hypersensitivity and infusion reactions; elevated liver enzymes and C. difficile-associated diarrhea are label warnings.
- Orbactiv and Kimyrsa can falsely prolong aPTT for up to 120 hours. Intravenous unfractionated heparin is contraindicated for 120 hours after either product.
- Vibativ can injure the kidneys. In pneumonia trials, patients with pre-existing moderate or severe kidney impairment had higher mortality with Vibativ than with vancomycin; its label calls for renal monitoring.
- Vibativ may cause fetal harm based on animal studies. Its label calls for pregnancy status verification in patients of reproductive potential before treatment and describes contraception precautions.
- Vibativ also interferes with coagulation tests. Its label contraindicates intravenous unfractionated heparin with Vibativ administration; aPTT may be artificially prolonged for 0 to 18 hours after administration.
- Serious hypersensitivity, infusion reactions, and C. difficile-associated diarrhea are described in the labels. Severe or persistent symptoms need clinical assessment.
Product quality
Product identity and quality
The named products are sterile prescription medicines prepared for intravenous use.
Exact oritavancin product
Orbactiv and Kimyrsa differ in vial strength, infusion duration, preparation, and compatible diluents.
Vial strength
A vial's milligrams identify its contents, not the dose selected for a patient.
Mechanism
How it is proposed to work
The antibiotics interfere with bacterial cell-wall formation, but they are different molecules.
Oritavancin and telavancin also disrupt bacterial membrane function. Activity against a particular organism must be assessed using susceptibility information.
FAQ
Common questions
Do all three treat hospital-acquired pneumonia?
No. Vibativ has a specific adult indication for hospital-acquired or ventilator-associated pneumonia caused by susceptible S. aureus when alternatives are unsuitable. The cited Dalvance and oritavancin labels cover specified skin infections.
Can oritavancin affect blood-clotting tests?
Yes. Orbactiv and Kimyrsa can falsely prolong aPTT for up to 120 hours. Intravenous unfractionated heparin is contraindicated for 120 hours after either product.
Details
Technical details
Sources
References
- 1.
DailyMed. Dalvance prescribing information
- 2.
DailyMed. Orbactiv prescribing information
- 3.
DailyMed. Kimyrsa prescribing information
- 4.
DailyMed. Vibativ prescribing information
- 5.
PubMed. Once-weekly dalbavancin versus daily conventional therapy for skin infection
doi:10.1056/NEJMoa1310480 PMID:24897082